GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray
- First Posted Date
- 2005-04-29
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT00109486
- Locations
- π©π°
GSK Investigational Site, Randers, Denmark
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
- Conditions
- First Posted Date
- 2005-04-27
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4116
- Registration Number
- NCT00109330
- Locations
- πΊπΈ
GSK Investigational Site, Norfolk, Virginia, United States
Perennial Allergic Rhinitis Study In Pediatric Subjects
- Conditions
- First Posted Date
- 2005-04-21
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 558
- Registration Number
- NCT00108914
- Locations
- πΈπ°
GSK Investigational Site, Nitra, Slovakia
The CLEVER Study - Coreg And Left Ventricular Mass Regression
- Conditions
- Interventions
- First Posted Date
- 2005-04-14
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 287
- Registration Number
- NCT00108082
- Locations
- πΊπΈ
GSK Investigational Site, Milwaukee, Wisconsin, United States
A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
- Conditions
- First Posted Date
- 2005-04-14
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 701
- Registration Number
- NCT00108095
- Locations
- πͺπΈ
GSK Investigational Site, Santiago de Compostela, Spain
Seasonal Allergic Rhinitis In Pediatric Subjects
- Conditions
- First Posted Date
- 2005-04-08
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 576
- Registration Number
- NCT00107757
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
- Conditions
- First Posted Date
- 2005-04-08
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT00107718
- Locations
- π¦πΊ
GSK Investigational Site, Nedlands, Western Australia, Australia
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
- First Posted Date
- 2005-03-21
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT00105950
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
- Conditions
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 722
- Registration Number
- NCT00104403
- Locations
- π¬π§
GSK Investigational Site, Shrewsbury, United Kingdom
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures
- Conditions
- Interventions
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 153
- Registration Number
- NCT00104416
- Locations
- πΊπ¦
GSK Investigational Site, Lviv, Ukraine